Compare CYN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYN | PLUR |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | Israel |
| Employees | 62 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 25.5M |
| IPO Year | 2021 | 2001 |
| Metric | CYN | PLUR |
|---|---|---|
| Price | $1.23 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 197.7K | 10.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | N/A | ★ N/A |
| Revenue | $368,138.00 | ★ $1,336,000.00 |
| Revenue This Year | $3,359.28 | $97.38 |
| Revenue Next Year | $347.47 | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $1.22 | $2.22 |
| 52 Week High | $41.54 | $5.96 |
| Indicator | CYN | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 29.08 |
| Support Level | N/A | N/A |
| Resistance Level | $1.76 | $2.58 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 27.54 | 0.00 |
Cyngn Inc is an industrial autonomous vehicle technology company, focused on addressing industrial uses for autonomous vehicles. It develops full-stack autonomous driving software, DriveMod, which is integrated into vehicles manufactured by original equipment manufacturers during the assembly process. The company designs its software to be compatible with a range of sensors and hardware components and integrates it with its own systems to enable autonomous vehicle functionality.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.